Orchid Chemicals and Pharmaceutical received approval from the FDA for its abbreviated new drug application (ANDA) of Cephalexin oral suspension. This is an off-patent molecule that forms part of Orchid's distribution alliance with U.S. generic pharma company, Par Pharmaceuticals.
The company believes that given the complexity of the formulation, it would have a good positioning in the generics market. Its Cephalexin capsules are already marketed in the U.S. in distribution partnership with Par. With the latest ANDA approval, the number of dosage forms, oral solids and injections distributed by Orchid in the U.S. stands at 12.
